Inhalation Sciences Sweden AB Stock

Equities

ISAB

SE0009983893

Advanced Medical Equipment & Technology

End-of-day quote NORDIC GROWTH MARKET 06:00:00 2024-01-30 pm EST 5-day change 1st Jan Change
4.34 SEK +6.90% Intraday chart for Inhalation Sciences Sweden AB -.--% +7.43%
Sales 2024 * 38.3M 3.5M Sales 2025 * 65.8M 6.01M Capitalization 65.83M 6.02M
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * 1.45 x
Net cash position 2024 * 10.3M 942K Net cash position 2025 * - 0 EV / Sales 2025 * 1 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 8
Yield 2024 *
-
Yield 2025 *
-
Free-Float 70.14%
More Fundamentals * Assessed data
Dynamic Chart
Inhalation Sciences Sweden AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Inhalation Sciences Sweden AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Inhalation Sciences Signs New Partnership with Actarmo Medical CI
Inhalation Sciences AB Secures Product Service Contract Worth EUR 47,000 CI
Inhalation Sciences Sweden AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Inhalation Sciences Secures New Purchase Order Worth EUR 276,450 CI
Inhalation Sciences Sweden AB Secures New Order Worth 54,700 Euro CI
Inhalation Sciences Secures EUR 188,900 Order from Top-Five Global Generics Manufacturer CI
Inhalation Sciences Signs Collaboration Agreement with Leading Indian Multinational Pharma Company CI
Inhalation Sciences Sweden AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Inhalation Sciences Wins New Purchase Order from Asian Distributor Worth USD 94,000 CI
Inhalation Sciences Receives Purchase Order Worth 125.8 KEURO from International Distributor for Asia CI
Inhalation Research Services Wins New Order Worth 98,000 from Returning US Customer CI
Inhalation Sciences Sweden AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Inhalation Sciences Receives New Order Worth 53,000 from Return Customer CI
More news
1 day+6.90%
3 months+3.58%
6 months-9.21%
Current year+7.43%
More quotes
Current year
3.85
Extreme 3.85
4.99
1 year
2.43
Extreme 2.43
4.99
3 years
2.43
Extreme 2.43
12.50
5 years
2.43
Extreme 2.43
14.55
10 years
2.43
Extreme 2.43
15.48
More quotes
Managers TitleAgeSince
Chief Executive Officer - 18-11-30
Founder - 04-12-31
- -
Members of the board TitleAgeSince
Chairman - 20-04-30
Founder - 04-12-31
Chief Executive Officer - 18-11-30
More insiders
Inhalation Sciences Sweden AB is a Sweden-based company, which develops and sells labtech equipment for inhalation research. The Company’s primary product is PreciseInhale, which is a laboratory system that lets scientists measure how inhaled particles act in lungs and affect human health. PreciseInhale is a dry powder aerosol research and development system, which generate aerosols and data of a quality. The system helps to eliminate poor candidate drugs before clinical trials. The secondary product is LaminarPace, a tool for drying small amounts of drug substance. The Company’s customers comprise Dow Chemical Group, Kings College London and Karolinska Institutet, among others. The Company’s main shareholder is Nordnet Pensionsforsakring.
More about the company

Quarterly revenue - Rate of surprise